Product logins

Find logins to all Clarivate products below.


Immunology | Inflectra/Remsima Launch Tracking (Germany) | Wave 3 | 2016

Inflectra/Remsima (Germany) Wave 3 is the third in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima, two different brands of Celltrion’s infliximab biosimilar CT-P13. Unlike previous reports in this series, this report also tracks Biogen’s Benepali, the only etanercept biosimilar to launch in the EU to date.

We surveyed rheumatologists and gastroenterologists in Germany to determine their level of awareness of and experience and satisfaction with Inflectra, Remsima, and Benepali in order to identify key drivers and barriers to these biosimilars’ uptake and to gauge physicians’ level of contact with marketers of Inflectra, Remsima, Remicade, and Benepali.

Questions Answered in This Report:

  • Since Wave 1 was fielded one year ago, how have awareness and perceptions of infliximab biosimilars changed among rheumatologists and gastroenterologists in Germany, and how do their awareness and perceptions of Benepali compare with those of Inflectra/Remsima at three months’ postlaunch?
  • Among German rheumatologists and gastroenterologists, what are the key drivers of the uptake of Inflectra/Remsima and Benepali, and what proportion of patients are switched to these agents from Remicade or Enbrel?
  • What proportion of German rheumatologists and gastroenterologists have been actively encouraged to use Inflectra/Remsima or Benepali or to meet a prescribing quota for these biosimilars?
  • What benefit would another biosimilar need to offer for German rheumatologists and gastroenterologists to preferentially prescribe it in place of Inflectra/Remsima or Benepali?

Related Market Assessment Reports

Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Forecast – Ophthalmology
In 2023, sales of branded biologics in ophthalmology exceeded $9.2 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period…
Report
Biosimilars – Forecast – Respiratory
In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…
Report
Biosimilars – Forecast – Neurology
In 2023, sales of branded MAb biologics in neurology exceeded $10 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2023-2033 forecast period, the…
Report
Biosimilars – Forecast – Endocrinology
In 2023, sales of insulins at the ex-manufacturer price level exceeded $19 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3…